about
Actions of two main metabolites of propiverine (M-1 and M-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes.Association of change in estradiol to lower urinary tract symptoms during the menopausal transition.Altered detrusor gap junction communications induce storage symptoms in bladder inflammation: a mouse cyclophosphamide-induced model of cystitis.The role of sacral neuromodulation in double incontinence.Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor.New roles for muscarinic receptors in the pathophysiology of lower urinary tract symptoms.The potential of hormones and selective oestrogen receptor modulators in preventing voiding dysfunction in ratsCalcium Antagonists Use and Its Association with Lower Urinary Tract Symptoms: A Cross-Sectional Study.Pharmacodynamics of propiverine and three of its main metabolites on detrusor contractionElectrical stimulation for the treatment of lower urinary tract dysfunction after spinal cord injuryMuscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladderPharmacological therapy of female urinary incontinence.Big-conductance Ca2+-activated K+ channels in physiological and pathophysiological urinary bladder smooth muscle cells.Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.Pharmacological treatment of pure stress urinary incontinence: a narrative review.Actions of the new antimuscarinic compound Lu 25-109 on isolated human and pig detrusor.An investigation of factors predicting the type of bladder antimuscarinics initiated in Medicare nursing homes residents.The role of the prostacyclin receptor antagonist RO3244019 in treating neurogenic detrusor overactivity after spinal cord injury in rats.Antimuscarinic drugs for the treatment of female urinary incontinence.
P2860
Q30483622-0DB8FB06-C5BA-48A0-A43D-4893A784AC21Q33619915-F2864C8D-A2A6-482E-89FA-CD82044D4123Q34010976-B147865A-1B02-41B3-9DAE-08994754B5D3Q34161961-48693232-F679-48CB-A25B-447D7CAC2FE7Q34285907-1A967502-EC9E-4595-B7D1-84A9B2F8EAEFQ34334942-209FC6CD-2803-493B-A3F5-3F05F9F44AD1Q34358011-FA64096C-8254-4092-A050-497FFC678613Q34785537-71DE668E-9CA7-49B1-91FC-E64A394D01C9Q35048983-3924DC83-85D0-40F4-9658-F60635E98DD1Q35418474-3871EA2E-E3AD-4FC6-B8A2-7FFBA64DD7F4Q35546189-980D7F15-7E35-480E-823A-0ABEA736A855Q35697774-6E0F5F3E-7759-4E42-8187-33705332DF5BQ37183270-A9A5027B-9B96-41ED-BDCE-542071195048Q37405499-905F3918-1AF9-4D8B-99D7-4178E9065DF9Q38335674-EE53B9F1-F02E-4480-8A5F-CDB39D21EA25Q42164049-582EC71C-6997-44C2-9499-B6B0E8645D7AQ47143545-B0818BF4-19AA-419A-AC22-6504C132A4A9Q51765630-041E3A72-6A37-46EB-98BC-CA6C1D519C16Q51817526-7001A55B-E5C0-472B-838F-26D1757E7F3E
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The pharmacological treatment of urinary incontinence.
@ast
The pharmacological treatment of urinary incontinence.
@en
type
label
The pharmacological treatment of urinary incontinence.
@ast
The pharmacological treatment of urinary incontinence.
@en
prefLabel
The pharmacological treatment of urinary incontinence.
@ast
The pharmacological treatment of urinary incontinence.
@en
P2093
P2860
P1433
P1476
The pharmacological treatment of urinary incontinence
@en
P2093
A E Finkbeiner
K E Andersson
L D Cardozo
R Vela Navarrete
P2860
P304
P356
10.1046/J.1464-410X.1999.00397.X
P577
1999-12-01T00:00:00Z